1. 3 potential blockbusters under FDA review — AbbVie gets the most out of its workers — Roche/Exelixis’ Cotellic fizzles in melanoma study — See more on our front page news

    TRY TWO WEEKS OF OUR EMAIL NEWS HEADLINES FOR FREE
    Dismiss Notice
  2. Dealing with a potential legal issue at work?Ask an Employment Attorney -- a chance to discuss employment-related legal issues with a practicing attorney with over 20 years in employment law experience.
    Dismiss Notice

Recruiter called...

Discussion in 'BioDelivery Sciences' started by anonymous, Apr 3, 2017 at 6:54 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    A recruiter called me about a position with this company. How is it? How are the drugs? What are they paying for salary?
     

  2. anonymous

    anonymous Guest

    Look at pain market...all is in a decline and most managedcare is paying for generic 1st...copay cards are going to get you in trouble with opioids
     
  3. anonymous

    anonymous Guest

    What territory?
     
  4. anonymous

    anonymous Guest

     
  5. anonymous

    anonymous Guest

    Investors must be backing out again. Mark has broken the silence with another bullshit press release about a once monthly injection, but he still won't come clean about sales on the earnings calls. Keep giving it away - It's a recipe for success.
     
  6. anonymous

    anonymous Guest

     
  7. anonymous

    anonymous Guest

    The PR had nothing to do with a once-monthly, but rather the addtion of Belbuca to CVS/Caremark formularies. That is much more of a big deal than you realize
     
  8. anonymous

    anonymous Guest

    It appears that they are looking for very young and inexperienced reps.
    They may want to find people who are willing to sell off label.
     
  9. anonymous

    anonymous Guest

     
  10. anonymous

    anonymous Guest

    Really? The flagship product, Belbuca, has the indication for chronic moderate to severe pain. There really is no way to go off label with it. No one is going to use it for acute pain, and the dose it too low to treat addiction. BDSI is fine just going after the chronic pain market.
     
  11. anonymous

    anonymous Guest

    Recruiter doesn’t know so ima ask on CP is there a drug test? T H C mainly
     
  12. anonymous

    anonymous Guest

    You need a drug test if you think you can sell this dud.
     
  13. anonymous

    anonymous Guest

    Dud?
     
  14. anonymous

    anonymous Guest

    No drug testing or pre-employment stuff. Since they don’t do PE a lot of us have a side hustle. As long as your other companies drugs don’t compete against Bel & Bun.
     
  15. anonymous

    anonymous Guest

    There is definitely a preemployment urine drug screening
     
  16. anonymous

    anonymous Guest

    We are so cheap we don’t do drug screens.
     
  17. anonymous

    anonymous Guest

    I was never drug screened
     
  18. anonymous

    anonymous Guest

    I got a call from a recruiter about this company.
    Messaged a couple reps on LinkedIn and got a lot mixed reviews about the company. Talked to several pain drs and got the same mixed feedback about the drug and coverage.
    I’m on the fence about taking the interview can anybody share anything positive on why they came here to work? I know this is cafepharma but serious replies only. Thanks.
     
  19. anonymous

    anonymous Guest

    There are a lot of people looking for other jobs. The bonus structure is not beneficial or motivating. Company car allowance, no gas reimbursement. It's a great entry level job, but that's about it. Lots of turnover.
     
  20. anonymous

    anonymous Guest

    The product is actually sellable, and has fairly good insurance coverage. The job in itself is great, but the company could use work. Agreed with other poster, the bonus structure is really terrible.